Trial Profile

Phase III study of F901318 for invasive aspergillosis

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 13 Jul 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Olorofim (Primary)
Indications Aspergillosis; Invasive bronchopulmonary aspergillosis
Focus Registrational; Therapeutic Use
Sponsors F2G

Most Recent Events

11 Jul 2016 According to an F2G media release, the company plans to initiate this trial in 1H 2017.
24 Jun 2016 New trial record
20 Jun 2016 According to F2G media release, thae company plans to initiate this trial in the second half of 2016.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com